Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND EBITDA Margin

EBITDA as a percentage of revenue.

Ascendis Pharma A/SNASDAQ: ASND

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin widens to 35.0%

EBITDA Margin was 35.0% in Q3 FY2026, up 59.9 pp from a year earlier. On a trailing-twelve-month basis it was 21.5%, up 42.1 pp year over year. Over 3 fiscal years it widened by 1018.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 13 analysts of 96.8% for the fiscal year ending Dec 2026, up from -15.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
35.0%+15.2 pp QoQ
Last fiscal yearDec 2025
-15.9%+63.9 pp YoY
LTMSep 2026
21.5%+42.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+59.9 pp-95.3 pp-155.3 pp
1 year+63.9 pp+112.7 pp+48.8 pp
3 years+1018.2 pp+73.4 pp-944.8 pp
5 years+79.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-15.9%
Year-over-year change
+63.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ASND compares with its peers on the latest reported figures

  • ASND's LTM Sep 2026 EBITDA Margin of 21.5% is the 3rd highest of the 10 companies compared; the peer median is -8.0%.
  • Its year-over-year change of +42.1 pp is the 3rd highest of 10, against a peer median of +0.3 pp.
  • Over three fiscal years its change of +1018.2 pp compares with a peer median of +6.3 pp.
ASND Competitors Peer median
EBITDA Margin for ASND and competitors
Company Period LTM level YoY 3-year change
UTHRUnited Therapeutics CorporationLTM Jun 202653.1% -2.6 pp+3.4 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202625.7% +0.3 pp+7.4 pp
ASNDAscendis Pharma A/SLTM Sep 202621.5% +42.1 pp+1018.2 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202614.7% +16.6 pp+67.2 pp
CORTCorcept Therapeutics IncorporatedLTM Jun 20263.5% -14.4 pp-20.8 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-8.0% -32.9 pp+5.1 pp
SEPNSepterna, Inc.LTM Sep 2026-59.3% +282.9 pp—
INSMInsmed IncorporatedLTM Jun 2026-67.8% +167.9 pp-10.9 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-511.5% -539.6 pp+799.5 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
Peer median (excluding ASND) -8.0%+0.3 pp+6.3 pp

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.